<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912223</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0701</org_study_id>
    <secondary_id>U01HL069294</secondary_id>
    <secondary_id>U01HL06929406</secondary_id>
    <secondary_id>5U24CA076518</secondary_id>
    <nct_id>NCT00912223</nct_id>
    <nct_alias>NCT00867074</nct_alias>
  </id_info>
  <brief_title>Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)</brief_title>
  <official_title>A Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response (BMT CTN #0701)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood stem cell transplants are one treatment option for people with lymphoma or other types
      of blood cancers. For this type of treatment, family members or unrelated donors with a
      similar tissue type usually donate their blood stem cells to the transplant patients. This
      study will evaluate the effectiveness of a type of blood stem cell transplant that uses lower
      doses of chemotherapy in people with relapsed follicular non-Hodgkin's lymphoma (NHL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follicular NHL, a type of blood cancer, is the second most common type of non-Hodgkin's
      lymphoma, with approximately 15,000 new cases being diagnosed each year in the United States.
      Chemotherapy is a common treatment option for people with NHL, and at first most people
      achieve cancer remission with initial chemotherapy. However, after the initial chemotherapy,
      people with this disease typically experience a continuous pattern of relapse that results in
      progressively shorter remission durations. A blood stem cell transplant is another treatment
      option for people with follicular NHL. In a blood stem cell transplant procedure, healthy
      blood stem cells are taken from a donor and transplanted into the patient. The cells can be
      donated by a family member or an unrelated donor who has a similar tissue type. Typically,
      people who are undergoing a blood stem cell transplant receive high doses of chemotherapy
      before the transplant to prepare their bodies to accept the donor stem cells. In this study,
      participants will undergo a type of stem cell transplant called a nonmyeloablative
      transplant, which involves a reduced intensity method of transplantation that does not
      require high doses of chemotherapy. The purpose of the study is to examine the effectiveness
      of a nonmyeloablative allogeneic blood stem cell transplant at improving survival rates in
      people with relapsed follicular NHL.

      This study will enroll people with relapsed follicular NHL. At a baseline study visit,
      participants will undergo a medical history review, physical examination, blood collection,
      lung function testing, computed tomography (CT) scans, a bone marrow biopsy, and
      questionnaires to assess quality of life. Participants will be admitted to the hospital and
      on various days in the 2 weeks before the transplant, they will receive fludarabine,
      cyclophosphamide, rituximab, which are cancer medications, and tacrolimus, a medication that
      will help prevent graft-versus-host disease (GVHD), which is an attack by the donor cells on
      the body's normal tissues. Participants will then undergo the blood stem cell transplant. At
      various times during the 2 weeks after the transplant, participants will receive rituximab
      and methotrexate, which is another medication to prevent GVHD. They will also receive
      tacrolimus for at least 6 months to help prevent GVHD. Participants will remain in the
      hospital for as long as necessary to recover from the transplant. Follow-up study visits will
      occur weekly for Weeks 1 to 14, and then at Months 6, 12, 18, and 24. At each study visit,
      select baseline procedures will be repeated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Year 2</time_frame>
    <description>Patients are considered a failure for this endpoint if they die, or if they relapse/progress or receive anti-lymphoma therapy not including planned post-transplant radiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft Failure</measure>
    <time_frame>Day 30</time_frame>
    <description>Primary graft failure is defined as a donor peripheral blood T cell chimerism &lt; 5% at Day +30 post-transplant. Secondary Graft Failure is defined as documented engraftment followed by loss of graft as defined by donor peripheral blood T cell chimerism &lt; 5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Cell Engraftment</measure>
    <time_frame>Days 30 and 100</time_frame>
    <description>Donor engraftment is defined as &gt; 5% donor peripheral blood T cell chimerism by Day +30 post-transplant in the setting of Absolute Neutrophil Count (ANC) recovery (ANC &gt;500/mm^3 for 3 consecutive days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Neutrophil Recovery</measure>
    <time_frame>Day 60</time_frame>
    <description>Neutrophil Recovery is defined as ANC &gt; 500/mm^3 for 3 consecutive days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft-versus-Host Disease (GVHD)</measure>
    <time_frame>Day 100</time_frame>
    <description>The event is the incidence of grades II-IV acute GVHD from day of transplant, where grade IV is worst. The first day of acute GVHD onset at a certain grade will be used to calculate a cumulative incidence curve for that acute GVHD grade. GVHD should be monitored in accordance with BMT CTN manual of procedures guidelines. Acute GVHD grading was based on the consensus conference criteria (Przepiorka, et. al., 1994) and the Center for International Blood and Marrow Transplant Research (CIBMTR) grading criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>Year 2</time_frame>
    <description>The event is the incidence and severity of chronic GVHD from day of transplant, a cumulative incidence curve will be computed along with a 95% confidence interval at two years post-transplant. Death prior to occurrence of chronic GVHD will be considered as a competing risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Years 2 and 3</time_frame>
    <description>The event is death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Mortality (TRM)</measure>
    <time_frame>Year 3</time_frame>
    <description>The event is death occurring in patients in continuous complete remission. The TRM distribution will be estimated by the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>Year 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Year 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Reconstitution</measure>
    <time_frame>Year 1</time_frame>
    <description>Quantitative immunoglobulins (IgG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Toxicities</measure>
    <time_frame>Year 2</time_frame>
    <description>Number of participants that experiences at least one grade 3 - 5 toxicity during the first two years, where grade 5 is worst. Toxicity grades are based on the NCI CTCAE Version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Rituximab (RTX) Levels</measure>
    <time_frame>Baseline, Days 28 and 365</time_frame>
    <description>RTX concentration levels within participants</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplant</intervention_name>
    <description>NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
The conditioning regimen will consist of the following:
Rituxan 375 mg/m^2 on Day -13
Rituxan 1000 mg/m^2 on Days -6, +1, and +8
Fludarabine 30 mg/m^2 on Days -5 to -3
Cyclophosphamide 750 mg/m^2 on Days -5, -4, -3
Day 0 will be the day of the transplant.
The GVHD prophylaxis will consist of the following:
Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.
Methotrexate 5 mg/m^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11.</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have confirmed CD20+ follicle center lymphoma that meets one of the following:

               1. Histologically confirmed recurrent Revised European American Lymphoma (REAL)
                  Classification CD20+ follicle center lymphoma, follicular grades I and II

               2. Histologically confirmed World Health Organization (WHO) classification CD20+
                  follicular lymphoma grades 1, 2, or 3a.

                  For either classification, the diffuse component of large cleaved cells (if
                  present) cannot be greater than 50% of cellularity. Patients do not have to
                  express t(14;18) to be eligible.

          -  Any number of prior regimens (including autologous hematopoietic cell transplantation
             [HCT]); the most recent prior regimen must have occurred more than 28 days before
             study entry

          -  Must demonstrate chemosensitive or radiosensitive disease to most recent prior regimen
             and meet one of the following criteria:

               1. Patients in second or subsequent complete remission (CR)

               2. Patients in first or subsequent partial remission (PR)

               3. Patients experiencing a relapse that demonstrates a response, as defined as
                  largest nodal mass less than or equal to 3 cm or greater than or equal to 50%
                  reduction in estimated lymph node volume measured as a product of bi-dimensional
                  measurements (see protocol for detailed definition).

               4. Patients with stable follicular lymphoma are eligible if all lymph node masses
                  are less than or equal to 3 cm and are smaller or unchanged in size to the most
                  recent salvage regimen.

          -  Patients with human leukocyte antigen (HLA)-matched donors that meet the following
             criteria:

               1. 6/6 HLA-matched related donor. HLA typing must be performed by DNA methods for
                  HLA-A and B at intermediate (or higher) resolution, and DRB1 at high resolution.
                  The donor must be willing to donate peripheral blood stem cells and meet
                  institutional criteria for stem cell donation. The donor must be medically
                  eligible to donate stem cells according to individual transplant center criteria;
                  or,

               2. 8/8 HLA-matched unrelated donor. HLA typing must be performed by DNA methods for
                  HLA-A, B, C, and DRB1 at high resolution. The donor must be willing to donate
                  peripheral blood stem cells and meet National Marrow Donor Program (NMDP)
                  criteria for stem cell donation. The donor must be medically eligible to donate
                  stem cells according to NMDP criteria.

          -  Patients with adequate organ function, as measured by the following:

               1. Heart: Left ventricular ejection fraction at rest greater than 45%

               2. Lungs: Diffusing capacity of the lung for carbon monoxide (DLCO), forced
                  expiratory volume in one second (FEV1), or forced vital capacity (FVC) greater
                  than 50% of predicted (corrected for hemoglobin). For patients in whom pulse
                  oximetry is performed, baseline O2 saturation greater than 85% (when lung
                  function testing cannot be performed due to age restrictions)

               3. Liver: Bilirubin less than two times the upper limit of normal for age as per
                  local laboratory; alanine aminotransferase (ALT) and aspartate aminotransferase
                  (AST) less than three times the upper limit of normal as per local laboratory

               4. Kidney: Calculated or measured creatinine clearance greater than or equal to 40
                  mL/min; if creatinine is greater than or equal to 1.5 mg/dL then 24-hour urine
                  for measured creatinine clearance should be performed.

        Exclusion Criteria:

          -  Patients in first CR

          -  Karnofsky performance score less than 70%

          -  Patients with follicular lymphoma that demonstrates evidence of histologic
             transformation. In the presence of B symptoms, rapid growth of a single dominant site,
             or prolonged (&gt; 2 yrs) interval since last tissue diagnosis, investigators are
             encouraged to consider re-biopsy of nodes prior to enrollment.

          -  Uncontrolled hypertension

          -  Uncontrolled bacterial, viral, or fungal infection (i.e., currently taking medication
             and progression of clinical symptoms)

          -  Prior cancer, other than resected basal cell carcinoma or treated cervical carcinoma
             in situ. Cancer treated with curative intent less than 5 years will not be allowed
             unless approved by the medical monitor or protocol chair. Cancer treated with curative
             intent greater than 5 years will be allowed.

          -  Pregnant or breastfeeding

          -  Seropositive for human immunodeficiency virus (HIV)

          -  Fertile men or women unwilling to use contraception from the time of initiation of
             conditioning until 6 months post-transplant

          -  Prior allogeneic HSCT

          -  Known anaphylactic reaction to rituximab

          -  Seropositive for any of the following: HIV ab, hepatitis B sAg or polymerase chain
             reaction (PCR)+, or hepatitis C ab or PCR+
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego (UCSD) Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)/Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)/Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland/Case Western</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State/Arthur G. James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, MD Anderson Cancer Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506-9162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-5156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <results_reference>
    <citation>Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML; Blood and Marrow Transplant Clinical Trials Network. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2016 Aug;22(8):1440-1448. doi: 10.1016/j.bbmt.2016.04.014. Epub 2016 Apr 23.</citation>
    <PMID>27118571</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <results_first_submitted>August 5, 2016</results_first_submitted>
  <results_first_submitted_qc>September 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2016</results_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicular Non-Hodgkin's Lymphoma</keyword>
  <keyword>Hematopoietic Stem Cell Transplant (HSCT)</keyword>
  <keyword>Non-Myeloablative Transplant (NST)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Findings will be published in a manuscript.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between April 2009 and November 2012 from 21 different transplant centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplant</title>
          <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not transplanted</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transformed disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Received transplant</population>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplant</title>
          <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="29" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Score</title>
          <description>Assesses patient self-perceived global quality of life and functioning on a scale of 0 - 100; where 100 equals normal quality of life with no evidence of disease, 90 equals ability to carry on normal activity with minor signs/symptoms of disease, and 80 equals normal activity with effort and some signs/symptoms of disease.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidity Index Score</title>
          <description>Comorbidity is graded on a scale of 0 to 6 based on the adjusted risk of mortality and the sum of scores result in a single comorbidity index score for a participant. A score of zero indicates that no comorbidities were found. The higher the score, the more likely the predicted outcome will result in mortality.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Status</title>
          <description>Disease status is categorized best to worst by second/subsequent complete remission (CR2), first partial remission (PR1), second partial remission (PR2). Complete remission criteria is disappearance of all evidence of disease and partial remission criteria is regression of measurable disease and no new sites.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CR2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ PR2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Prior Chemotherapy Regimens</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Type (HLA match)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Matched Related Donor (6/6 allele)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Matched Unrelated Donor (8/8 allele)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recipient Cytomegalovirus Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>Patients are considered a failure for this endpoint if they die, or if they relapse/progress or receive anti-lymphoma therapy not including planned post-transplant radiation.</description>
        <time_frame>Year 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>Patients are considered a failure for this endpoint if they die, or if they relapse/progress or receive anti-lymphoma therapy not including planned post-transplant radiation.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="60" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Failure</title>
        <description>Primary graft failure is defined as a donor peripheral blood T cell chimerism &lt; 5% at Day +30 post-transplant. Secondary Graft Failure is defined as documented engraftment followed by loss of graft as defined by donor peripheral blood T cell chimerism &lt; 5%.</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Failure</title>
          <description>Primary graft failure is defined as a donor peripheral blood T cell chimerism &lt; 5% at Day +30 post-transplant. Secondary Graft Failure is defined as documented engraftment followed by loss of graft as defined by donor peripheral blood T cell chimerism &lt; 5%.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Graft Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Graft Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Cell Engraftment</title>
        <description>Donor engraftment is defined as &gt; 5% donor peripheral blood T cell chimerism by Day +30 post-transplant in the setting of Absolute Neutrophil Count (ANC) recovery (ANC &gt;500/mm^3 for 3 consecutive days).</description>
        <time_frame>Days 30 and 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Cell Engraftment</title>
          <description>Donor engraftment is defined as &gt; 5% donor peripheral blood T cell chimerism by Day +30 post-transplant in the setting of Absolute Neutrophil Count (ANC) recovery (ANC &gt;500/mm^3 for 3 consecutive days).</description>
          <units>percentage of donor T-cell chimerism</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="25" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="25" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Neutrophil Recovery</title>
        <description>Neutrophil Recovery is defined as ANC &gt; 500/mm^3 for 3 consecutive days.</description>
        <time_frame>Day 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Neutrophil Recovery</title>
          <description>Neutrophil Recovery is defined as ANC &gt; 500/mm^3 for 3 consecutive days.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="8" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft-versus-Host Disease (GVHD)</title>
        <description>The event is the incidence of grades II-IV acute GVHD from day of transplant, where grade IV is worst. The first day of acute GVHD onset at a certain grade will be used to calculate a cumulative incidence curve for that acute GVHD grade. GVHD should be monitored in accordance with BMT CTN manual of procedures guidelines. Acute GVHD grading was based on the consensus conference criteria (Przepiorka, et. al., 1994) and the Center for International Blood and Marrow Transplant Research (CIBMTR) grading criteria.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft-versus-Host Disease (GVHD)</title>
          <description>The event is the incidence of grades II-IV acute GVHD from day of transplant, where grade IV is worst. The first day of acute GVHD onset at a certain grade will be used to calculate a cumulative incidence curve for that acute GVHD grade. GVHD should be monitored in accordance with BMT CTN manual of procedures guidelines. Acute GVHD grading was based on the consensus conference criteria (Przepiorka, et. al., 1994) and the Center for International Blood and Marrow Transplant Research (CIBMTR) grading criteria.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="16" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic GVHD</title>
        <description>The event is the incidence and severity of chronic GVHD from day of transplant, a cumulative incidence curve will be computed along with a 95% confidence interval at two years post-transplant. Death prior to occurrence of chronic GVHD will be considered as a competing risk.</description>
        <time_frame>Year 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic GVHD</title>
          <description>The event is the incidence and severity of chronic GVHD from day of transplant, a cumulative incidence curve will be computed along with a 95% confidence interval at two years post-transplant. Death prior to occurrence of chronic GVHD will be considered as a competing risk.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="48" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The event is death from any cause.</description>
        <time_frame>Years 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The event is death from any cause.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="72" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="70" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-related Mortality (TRM)</title>
        <description>The event is death occurring in patients in continuous complete remission. The TRM distribution will be estimated by the Kaplan-Meier curve.</description>
        <time_frame>Year 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Mortality (TRM)</title>
          <description>The event is death occurring in patients in continuous complete remission. The TRM distribution will be estimated by the Kaplan-Meier curve.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="8" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infections</title>
        <time_frame>Year 2</time_frame>
        <population>no data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Infections</title>
          <population>no data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <time_frame>Year 2</time_frame>
        <population>No data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <population>No data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Reconstitution</title>
        <description>Quantitative immunoglobulins (IgG)</description>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Reconstitution</title>
          <description>Quantitative immunoglobulins (IgG)</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431" lower_limit="79" upper_limit="1430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Toxicities</title>
        <description>Number of participants that experiences at least one grade 3 - 5 toxicity during the first two years, where grade 5 is worst. Toxicity grades are based on the NCI CTCAE Version 3.0.</description>
        <time_frame>Year 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Toxicities</title>
          <description>Number of participants that experiences at least one grade 3 - 5 toxicity during the first two years, where grade 5 is worst. Toxicity grades are based on the NCI CTCAE Version 3.0.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Rituximab (RTX) Levels</title>
        <description>RTX concentration levels within participants</description>
        <time_frame>Baseline, Days 28 and 365</time_frame>
        <population>Serum RTX concentrations were collected at baseline (n=57), day +28 (n=56), and day +365 (n=44) for a compliance rate of 92%, 90%, and 80% at the assigned time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Rituximab (RTX) Levels</title>
          <description>RTX concentration levels within participants</description>
          <population>Serum RTX concentrations were collected at baseline (n=57), day +28 (n=56), and day +365 (n=44) for a compliance rate of 92%, 90%, and 80% at the assigned time points.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42100" lower_limit="500" upper_limit="70200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341000" lower_limit="500" upper_limit="670000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="920" lower_limit="500" upper_limit="122000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years post-transplant</time_frame>
      <desc>Serious Adverse Events (AE) are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected grades 3-5 adverse events were required to be reported through the AE system per protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplant</title>
          <description>Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Mendizabal, PhD</name_or_title>
      <organization>The Emmes Corporation</organization>
      <phone>301-251-1161</phone>
      <email>amendizabal@emmes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

